Rhythm Pharmaceuticals’ shares rose 7.7% following the quarter, driven by a promising start to the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO) and encouraging early clinical data for its next-generation MC4R agonist, RM-718.
- Since FDA approval in March, over 400 start forms have been received from roughly 300 prescribers for IMCIVREE in HO, indicating strong early demand.
- Published Phase III HO TRANSCEND trial results and accompanying New England Journal of Medicine editorial have raised disease awareness and credibility of IMCIVREE among clinicians and payers.
- RM-718 Phase II open-label data show a meaningful mean BMI reduction of 11.6% at 16 weeks in HO patients, with a favorable tolerability profile and no generalized hyperpigmentation reported.
- Two patients discontinued RM-718 early due to injection site reactions and nausea; overall patient retention remains solid with 8 of 11 enrolled still on therapy.
- Rhythm is progressing toward anticipated regulatory submissions and launches in Japan and Europe, leveraging an established rare disease commercial platform.
Community Discussion